Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH6GLU)

Drug Name

TAK-754 Drug Info

Synonyms

BAX 888

Indication

Disease Entry	ICD 11	Status	REF
Haemophilia A	3B10.0	Phase 1/2	[1]

Cross-matching ID

TTD Drug ID: DMH6GLU

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Coagulation factor VIII (F8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Drotrecogin alfa	DM59JCN	Cerebrovascular ischaemia	8B1Z	Approved	[3]
Factor 8	DMAB6PM	Hemophilia	3B10.0	Approved	[4]
Eloctate	DMRCX8K	Haemophilia A	3B10.0	Approved	[5]
Efanesoctocog alfa	DM2CKIJ	Haemophilia A	3B10.0	Approved	[6]
SK-NBP601	DMUY09W	Hemophilia	3B10.0	Preregistration	[7]
Recombinant von Willebrand factor/recombinant Factor VIII complex	DM7JFDO	Von willebrand disease	3B12	Phase 3	[8]
N8-GP	DMY60DT	Factor VIII deficiency	3B10	Phase 3	[9]
OBI-1	DMENDP6	Factor VIII deficiency	3B10	Phase 3	[10]
BAY 94-9027	DM09M3H	Hemophilia	3B10.0	Phase 3	[11]
Plasma derived factor VIII PEGylated liposomal	DM1RWMY	Factor VIII deficiency	3B10	Phase 3	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor VIII (F8)	TT1290U	FA8_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03370172) A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion. U.S.National Institutes of Health.
2	A reprieve from hemophilia A, but for how long? Nat Biotechnol. 2020 Oct;38(10):1107-1109.
3	Protein C in critical illness. Am J Health Syst Pharm. 2009 Jun 15;66(12):1089-96.
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2607).
5	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
6	Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022 Feb 22;6(4):1089-1094.
7	Clinical pipeline report, company report or official report of SK Chemicals.
8	6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates. Transfus Med Hemother. 2009 December; 36(6): 409-418.
9	Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost. 2013 Apr;11(4):670-8.
10	Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar;21(2):162-70.
11	Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 Apr;12(4):488-96.